Smart ring maker Oura's listing setback reveals an old investment market proposition: calling yourself a "platform" does not mean the market will value you as one.

Oura attempted to go public in the US late last month but was forced to shelve its plans after failing to find enough buyers within its expected price range. The company blamed market volatility, but major stock indices were still near record highs at the time. According to The Wall Street Journal, the deeper conflict behind the failed IPO lies in the fact that Oura positioned itself as a technology data platform worth up to $15 billion, while potential investors saw nothing more than a polished health consumer product.

This positioning gap directly affects the valuation logic and raises fundamental questions among investors about the sustainability of the "single-product company" business model. For strategic investors such as Eli Lilly, which holds Oura pre-IPO shares, whether the company can prove the value of its data to healthcare payers will become the key focus of the next stage.

The listing curse of single-product companies

Previously, Peloton, Fitbit, Casper Sleep, and GoPro 鈥?these brands all quickly accumulated market enthusiasm before hitting the same wall: revenue growth depended on continuously selling new products rather than naturally expanding through the existing user base.

Jay Ritter, a professor at the University of Florida who studies IPOs, tracked 13 single-product consumer companies that went public between 2005 and 2024, and the results were striking: five years after listing, these companies' share prices had fallen an average of about 32% from their offering prices, while the broader market rose 49% over the same period; more than 1,200 other IPO companies in the same sample saw their share prices rise an average of 68%.

The only exception that outperformed the broader market was Roku 鈥?which transformed its streaming player business into an advertising platform and was acquired by Fox Corp. for $25 billion in June of this year. This case reveals the core path for single-product companies to break through their ceiling: the product itself must evolve into a platform, a subscription, or a service paid for by a third party other than the consumer.

Health tech analyst and consultant Stephanie Davis summarized consumer behavior as "extremely fast to adopt, extremely fast to abandon." This assessment precisely describes the structural vulnerability facing single-product consumer companies.

The gap between platform narrative and revenue reality

In its prospectus, Oura defined itself as a "health intelligence platform," claiming to have accumulated more than 40 billion hours of biometric tracking data, and hoped to layer software and AI capabilities on top of this to sell data services to pharmaceutical companies, employers, or insurance companies.

However, there remains a clear gap between current financial data and this vision. Its nine-month data ending June 30, 2025, showed that hardware sales (i.e., smart rings) accounted for about 80% of total revenue, while membership subscription revenue accounted for only 20%. Overall gross margin was approximately 55%, far below the typical level for digital health software companies.

Nevertheless, Oura sought a valuation multiple of about 10 times its revenue over the past 12 months. By comparison, when Fitbit was acquired by Google, the deal price was less than 2 times its revenue.

Robin Boldt, chief investment officer of healthcare-focused hedge fund Rock2 Capital, said:

"A hardware-centric business naturally corresponds to a lower revenue multiple. The ability to sustain or even accelerate subscription business growth is what can make public market investors more comfortable."

Customer retention challenges and marketing dependence

Oura currently has more than 5 million paying members, charging about $6 per month, and the company says its annual retention rate reaches 85%. But a true platform relies on deep user lock-in 鈥?developers make a living through the App Store, and drivers and restaurants depend on Uber to survive. Once users leave Oura, all they lose is their sleep history.

This relatively low level of user dependence forces Oura to continuously invest heavily in marketing 鈥?about one-fifth of revenue 鈥?to keep acquiring new buyers every year. This cost structure runs counter to the asset-light expansion model of true platform companies.

Three paths forward: diversification, platformization, and acquisition

Industry insiders believe there are roughly three paths for the long-term survival of single-product companies.

The first is product diversification. Garmin once centered on in-car GPS, and the rise of smartphones nearly destroyed that business line, but it successfully transformed by expanding into fitness watches, outdoor gear, and aviation and marine electronics.

The second is platformization. Roku sold players at razor-thin hardware margins and instead profited from advertising revenue and subscription revenue sharing.

For health wearable startups such as Oura and Whoop, the third path may hold the most potential 鈥?getting third parties to pay. ResMed's ventilators and Dexcom's glucose monitors achieved mass adoption because insurance companies covered the costs; Hinge Health's online physical therapy services are mainly paid for by employers and health plans.

Oura has already established partnerships with several medical institutions, for example, its temperature data has been integrated into the fertility app Natural Cycles. But to attract payers to actually pay, proving that the ring can accurately measure health indicators is not enough 鈥?it needs to prove that wearing the ring can effectively improve user health outcomes.

Being acquired may be the most direct path to profit for shareholders. Eli Lilly had already participated in investment before Oura's IPO and expressed interest in further increasing its stake. Given the medication management needs for drugs such as Zepbound and Mounjaro under Eli Lilly, access to real-time health data such as patients' sleep quality and exercise status has potential strategic value for the company.

Oura does not need to become the next Apple, or even the next Garmin. What it truly needs to prove to the market is that the data it collects is equally valuable to people other than consumers 鈥?and that it is not just a company selling expensive rings.